Skip to main content
OTLK
NASDAQ Life Sciences

FDA Accepts ONS-5010 BLA Resubmission, Sets July 29 PDUFA Date for Wet AMD Treatment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.171
Mkt Cap
$185.772M
52W Low
$0.161
52W High
$3.39
52W Position info
627% above low
Off High info
65% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

OTLK has more than doubled off its 52-week low of $0.161.

Summary

Outlook Therapeutics announced the FDA has accepted its Biologics License Application (BLA) resubmission for ONS-5010/LYTENAVA™ for wet AMD, setting a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026. This marks a critical step towards potential approval for their lead product.


Key Events · Product Development and Regulatory · OTLK

  • FDA Accepts BLA Resubmission

    The FDA acknowledged receipt and formally accepted the Biologics License Application (BLA) resubmission for ONS-5010/LYTENAVA™ for wet AMD.

  • PDUFA Date Set

    A Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026, has been set, indicating the target date for the FDA's decision.

  • Class 1 Review Designation

    The BLA resubmission was designated as a Class 1 review, resulting in an expedited 60-day review period from the resubmission date.

  • Critical Regulatory Progress

    This marks a significant advancement in the regulatory pathway for ONS-5010, a key product for a company previously flagged with "going concern" warnings.


Analysis · OTLK · Life Sciences

This filing confirms the FDA's formal acceptance of Outlook Therapeutics' resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA™ and establishes a Prescription Drug User Fee Act (PDUFA) goal date of July 29, 2026. For a company facing "going concern" warnings and significant dilution, this is a highly positive development, providing a clear and near-term timeline for a potential approval decision for its lead therapeutic candidate. The Class 1 review designation indicates an expedited 60-day review period, accelerating the process.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 49.5% of the 218 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, OTLK was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $185.8M. The 52-week trading range was $0.16 to $3.39. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

OTLK - Latest Insights

OTLK
Sep 30, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5989
Real-time Price: $0.469 info
Change: -$0.1299 (-22%) info
Market Cap: $111.986M info
OTLK
Sep 18, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.670776
Real-time Price: $0.469 info
Change: -$0.201776 (-30%) info
Market Cap: $111.986M info
OTLK
Aug 18, 2026, 5:29 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.6982
Real-time Price: $0.469 info
Change: -$0.2292 (-33%) info
Market Cap: $111.986M info
OTLK
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7973
Real-time Price: $0.469 info
Change: -$0.3283 (-41%) info
Market Cap: $111.986M info
OTLK
Aug 14, 2026, 7:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.790
Real-time Price: $0.469 info
Change: -$0.321 (-41%) info
Market Cap: $111.986M info